Lundbeck executive remains confident about Alzheimer's drug after new analysis

Even though Rexulti did not deliver quick results in phase III against Alzheimer's disease, Lundbeck's Head of R&D Johan Luthman still sees plenty of potential in the trial which is now set to be concluded in the new year.

Lundbeck EVP and Head of R&D Johan Luthman | Photo: PR / Lundbeck

Danish pharmaceutical company Lundbeck had hoped for quick, efficient results in the third clinical trial with Rexulti as a treatment for agitation in Alzheimer's patients, but this hope was soon extinguished.

That's the lay of the land early on Tuesday, after Lundbeck and partner company Otsuka stated that they would carry on the phase III trial with the drug after having received a new independent analysis of the preliminary results. Lundbeck plans to enroll all 330 patients, which the trial was scheduled for, and it will not discontinue the trial now, after having studied only 255 patients.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs